



Sp 1643
LP
10-9-98
FN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: R. Reiter and O. Witte
Serial No.: 09/038,261
Filed: March 10, 1998
Docket: 30435.54USU1
Title: PSCA: PROSTATE STEM CELL ANTIGEN

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on October 1, 1998.

By: Renato Marco P. Domingo
Name: Renato Marco P. Domingo

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Information Disclosure Statement (37 C.F.R. §1.97 (d))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 1-7
- ☒ Return postcard

RECEIVED
OCT 07 1998
GROUP 1800

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 N. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626)395-7801

By: Sarah B. Adriano
Name: Sarah B. Adriano
Reg. No.: 34,470
Initials: SBA


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert E. Reiter et al. **Examiner:** Not yet known
Serial No.: 09/038,261 **Group Art Unit:** 1643
Filed: March 10, 1998 **Docket No.:** 30435.54USU1
Title: PSCA: PROSTATE STEM CELL ANTIGEN

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 1, 1998.


By: Renato Marco P. Domingo



INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

RECEIVED
OCT 07 1998
GROUP 1800

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Sodee, D. Bruce et al., "Preliminary Imaging Results Using In-111 Labeled CYT-356 (Prostacint™) In The Detection of Recurrent Prostate Cancer," *Clinical Nuclear Medicine*, 21:759-767. 1996. (Exhibit 1)
- Israeli, Ron S. et al., "Expression of the Prostate-specific Membrane Antigen," *Cancer Research*, 54:1807-1811. April 1, 1994. (Exhibit 2)
- Wu, James T., "Assay for Prostate Specific Antigen (PSA): Problems and Possible Solutions," *Journal of Clinical Laboratory Analysis*, 8:51-62. 1994. (Exhibit 3)

- Horoszewicz, Julius S. et al., "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients," *Anticancer Research*, 7:927-936. 1987. (Exhibit 4)
- Cama, Cristoforo et al., "Molecular Staging of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen," *The Journal of Urology*, 153:1373-1378. May 1995. (Exhibit 5)
- Smith, Mitchell R. et al., "Prostate-specific Antigen Messenger RNA is Expressed in Non-Prostate Cells: Implications for Detection of Micrometastases," *Cancer Research*, 55:2640-2644. June 15, 1995. (Exhibit 6)
- Israeli, Ron S. et al., "Sensitive Nested Reverse Transcription Polymerase Chain Reaction Detection of Circulating Prostatic Tumor Cells: Comparison of Prostate-specific Membrane Antigen and Prostate-specific Antigen-based Assays," *Cancer Research*, 54:6306-6310. December 15, 1994. (Exhibit 7)

This statement should be considered because it is submitted before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. §1.98(d), copies of each document or other information listed on the enclosed Form 1449 are provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
Attorney for Applicants
Mandel & Adriano
35 N. Arroyo Parkway, Suite 60
Pasadena, CA 91103
(626) 395-7801

I hereby certify that this paper is being deposited with the Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Renato Marco P. Domingo 4/1/98
Renato Marco P. Domingo Date